Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial

2021 ◽  
Vol 158 ◽  
pp. 123-132
Author(s):  
Rolf D. Issels ◽  
Elfriede Noessner ◽  
Lars H. Lindner ◽  
Michael Schmidt ◽  
Markus Albertsmeier ◽  
...  
Keyword(s):  
Clinical Trial ◽  
High Risk ◽  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
Translational Research ◽  
Research Program ◽  
Randomised Clinical Trial ◽  
Regional Hyperthermia ◽  
Translational Research Program

scholarly journals Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma

JAMA Oncology ◽  
2018 ◽  
Vol 4 (4) ◽  
pp. 483 ◽  
Author(s):  
Rolf D. Issels ◽  
Lars H. Lindner ◽  
Jaap Verweij ◽  
Rüdiger Wessalowski ◽  
Peter Reichardt ◽  
...  
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
Long Term Outcomes ◽  
Regional Hyperthermia

Comparison of different systemic therapeutic regimes in resectable high-risk soft tissue sarcoma: Results of a network meta-analysis.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 11549-11549
Author(s):  
Jan Haussmann ◽  
Wilfried Budach ◽  
Edwin Boelke ◽  
Balint Tamaskovics ◽  
Freddy Joel Djiepmo Njanang ◽  
...  
Keyword(s):  
Overall Survival ◽  
High Risk ◽  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
Literature Search ◽  
Standard Treatment ◽  
Meta Analysis ◽  
Tumor Control ◽  
Regional Hyperthermia

11549 Background: The treatment of high-risk soft tissue sarcoma of the trunk or the extremities consists of surgical resection with risk-adapted radiation therapy. Further treatment options which can significantly improve local and systemic tumor control including chemotherapy are not well established. Due to the heterogeneity of disease different systemic approaches as well as their application during different time points have been attempted. Methods: We conducted a literature search for randomized clinical trials in the treatment of localized, resectable high-risk soft tissue sarcoma comparing different treatment modalities according to the PRISMA guidelines. We extracted published hazard ratios and number of events for the endpoints of overall and disease-free survival (OS; DFS) as well as local and distant recurrence-free interval (LRFI; DRFI). The different modalities were compared in a network meta-analysis against the defined standard treatment surgery ± radiotherapy using the inverse-variance heterogeneity model (ivhet) with the help of the Microsoft Excel add-in Meta-XL V5.3. Results: The literature search identified 25 studies including 3489 patients. The network analysis showed that adjuvant chemotherapy (adjCTx) results in a significant improvement in overall survival (HR = 0.86; CI-95%: 0.75-0.97; p = 0.017) compared to the standard treatment of surgery ± radiatherapy alone. Combined treatment with regional hyperthermia and neoadjuvant chemotherapy (HTx+nadjCTx) also improves OS (HR = 0.45; CI-95%: 0.20-1.00; p = 0.049). Preoperative chemotherapy alone (nadjCTx) as well as perioperative chemotherapy (periopCTx) resulted both in non-statistically significant improvements in OS (HR = 0.61; CI-95%: 0.29-1.29; p = 0.195) and (HR = 0.48; CI-95%: 0.15-1.55; p = 0.218). Histology-tailored neoadjuvant chemotherapy (tNaCTx) also showed no effect on overall survival (HR = 1.08; CI-95%: 0.45-2.61; p = 0.868). The analysis of DFS, LRFI and DRFI disclosed a similar pattern between the different treatment regimens. Conclusions: The addition of cytotoxic chemotherapy in resectable high-risk soft tissue sarcomas provides a measurable benefit in overall survival. Shifting of systemic therapy to the neoadjuvant setting and combination with regional hyperthermia might be favored. Predictive clinical and molecular markers are needed to evaluate and limit potentional risks prospectively going forward.

scholarly journals Effectiveness of Regional Hyperthermia With Chemotherapy for High-Risk Retroperitoneal and Abdominal Soft-Tissue Sarcoma After Complete Surgical Resection

2014 ◽  
Vol 260 (5) ◽  
pp. 749-756 ◽  
Author(s):  
Martin K. Angele ◽  
Markus Albertsmeier ◽  
Niclas J. Prix ◽  
Peter Hohenberger ◽  
Sultan Abdel-Rahman ◽  
...  
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Surgical Resection ◽  
Regional Hyperthermia ◽  
Complete Surgical Resection

scholarly journals Comparison of Two Chemotherapy Regimens (AI vs. EIA) Combined with Regional Hyperthermia (RHT) in High-Risk Soft-Tissue Sarcoma (HR-STS)

2012 ◽  
Vol 23 ◽  
pp. ix487 ◽  
Author(s):  
P.O. Aubele ◽  
E. Kampmann ◽  
G. Schuebbe ◽  
S. Abdel-Rahman ◽  
N. Dieterle ◽  
...  
Keyword(s):  
High Risk ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Regional Hyperthermia
Sign in / Sign up

Export Citation Format

Share Document